Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 415-490-5 | CAS number: 141773-73-1 HELVETOLIDE
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 29 May to 30 August 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study performed according to the OECD TG No. 414 without any deviation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.31 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other:
- Version / remarks:
- OPPTS 870.3800 Reproduction and Fertility Effects, August 1998.
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2-{(1RS)-1-[(1SR)-3,3-DIMETHYLCYCLOHEXYL]ETHOXY}-2-METHYLPROPYL PROPIONATE
- Molecular formula:
- C17 H32 O3
- IUPAC Name:
- 2-{(1RS)-1-[(1SR)-3,3-DIMETHYLCYCLOHEXYL]ETHOXY}-2-METHYLPROPYL PROPIONATE
- Reference substance name:
- 2-{(1RS)-1-[(1RS)-3,3-DIMETHYLCYCLOHEXYL]ETHOXY}-2-METHYLPROPYL PROPIONATE
- Molecular formula:
- C17 H32 O3
- IUPAC Name:
- 2-{(1RS)-1-[(1RS)-3,3-DIMETHYLCYCLOHEXYL]ETHOXY}-2-METHYLPROPYL PROPIONATE
- Reference substance name:
- 2-METHYL-2-{[(1RS,2RS)-2,6,6-TRIMETHYLCYCLOHEPTYL]OXY}PROPYL PROPIONATE
- Molecular formula:
- C17H32O3
- IUPAC Name:
- 2-METHYL-2-{[(1RS,2RS)-2,6,6-TRIMETHYLCYCLOHEPTYL]OXY}PROPYL PROPIONATE
- Test material form:
- liquid
- Details on test material:
- - Physical state: colourless liquid
- Storage condition of test material: Room temperature, under nitrogen
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited, Margate, Kent, CT9 4LT, England
- Age at study initiation: 8 to 10 weeks
- Weight at study initiation: 210 g to 319 g.
- Fasting period before study: none
- Housing: individually in solid-floor cages with appropriate bedding provided
- Diet: ad libitum (pelleted rodent diet, VRF1 (manufactured by SDS) supplied by Charles River (UK) Limited, Margate, Kent, CT9 4LT, England)
- Water: ad libitum
- Acclimation period: at least 2 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19°C to 23°C
- Humidity (%): 40% to 70%
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 2018-05-29 To: 2018-08-30
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5% (high viscosity)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
A weighed quantity of test item was added to the final preparation container, then 20 % of the final required volume of vehicle was added and stirred vigorously to form an emulsion. After further addition of vehicle and mixing, the resultant suspension was mixed with a laboratory homogeniser and then stirred for a minimum of 20 minutes thereafter.
Formulations were divided into daily aliquots and were stored refrigerated (2 °C to 8 °C) until at least 20 minutes before dosing on the day of use, when they were stirred before the start of dosing until the completion of their use for dosing, to ensure thorough re-suspension and homogeneity.
VEHICLE
- Justification for use and choice of vehicle (if other than water): based on previous toxicology studies
- Concentration in vehicle: 10, 30 and 100 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Stability: Stability of test item formulations prepared at concentrations of 1 to 100 mg/mL, spanning those used in this study (10 to 100 mg/mL), were examined in an earlier formulation validation study. Those formulations were found to be stable for 8 and 14 days when stored at room temperature (15 to 25 °C) and refrigerated (2 to 8 °C), respectively.
- Homogeneity and achieved concentrations: Duplicate samples were taken from the top, middle and bottom of each test item formulation prepared for use on the first day of dosing and on one occasion towards the end of the dosing period. One set of samples was analysed using a validated method (3) to confirm homogeneity and achieved concentrations by analysis by a gas chromatographic assay using flame ionisation detection. On these occasions, duplicate samples were also taken from the vehicle used to dose Controls and were analysed to confirm absence of test item.
Analysis of the samples confirmed homogeneity and achieved concentrations as well as absence of the test item in the vehicle. All remaining samples were retained as a contingency and stored refrigerated (approximately 2 ºC to 8 °C) and discarded once the final formulation analysis results were accepted. - Details on mating procedure:
- - Impregnation procedure: purchased timed pregnant
- Duration of treatment / exposure:
- From Day 6 to Day 19 of gestation inclusive
- Frequency of treatment:
- Once daily
- Duration of test:
- From Day 6 to Day 20 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 22 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected on the basis of results from existing toxicity data
- Rationale for animal assignment (if not random): random
Examinations
- Maternal examinations:
- CLINICAL OBSERVATIONS: Yes
- Time schedule: Twice daily for mortality and morbidity and were given a detailed clinical examination daily from the start of treatment
BODY WEIGHT: Yes
- Time schedule for examinations: by the supplier on Day 0 of gestation. At Sequani, body weights were recorded for all females daily from Day 5 to Day 20 of gestation.
FOOD CONSUMPTION : Yes
- The amount of food consumed by each animal was recorded over Days 6 to 9, 9 to 12, 12 to 15, 15 to 18 and 18 to 20 of gestation
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: The cranial and thoracic cavities were opened, a full internal examination was performed, and all macroscopic abnormalities were recorded. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes (right and left horn)
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [all per litter]
- Skeletal examinations: Yes: [all per litter]
- Head examinations: Yes: [half per litter] - Statistics:
- Data were processed to give group mean values and standard deviations, where appropriate.
Where the data allowed, the following methods were used for statistical analysis, comparing Groups 2, 3 and 4 against Group 1.
Depending on the nature of the data set that was to be analysed, appropriate tests were applied, Where parametric tests were appropriate they were preceded
by a check for homogeneity of variance using the Levene test and, where available, the Shapiro-Wilks test for normality. If either of these two assumptions failed, a log transformation was applied before retesting. If the transformation failed, appropriate non-parametric tests were applied.
Proportions of foetuses affected were treated as continuous non-parametric data, using onesided step-wise Jonckheere Tests.
Probability values of less than 5 % were regarded as providing sufficient evidence to reject the null hypothesis and therefore statistical significance was identified at the p<0.05 level. For illustrative purposes, significance levels of p<0.01 and p<0.001 were also noted. - Indices:
- Pre-implantation loss (%) = (no. of corpora lutea – no. of implantation sites) / no. of corpora lutea x 100
Post-implantation loss (%) = (no. of implantation sites – no. of live foetuses) / no. of implantation sites x 100 - Historical control data:
- Included in the report
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs in the surviving animals following administration of the test item.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- There were 2 deaths during the study, both were unrelated to the test item. Female 55, given 300 mg/kg/day, was euthanised on Day 12 of gestation due to 9 % body weight loss between Days 11 and 12 of gestation and clinical signs of pale extremities, cold body surface, rapid breathing and hunched postured. At necropsy, the lungs were red and the thoracic cavity had clear fluid contents.
Female 74, given 1000 mg/kg/day, was euthanised on Day 14 of gestation due to red discharge from the vulva. At necropsy, there was red contents in the vagina and the thymus was large.
Due to their isolated nature, these deaths were considered not to be related to the test item. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Following the first day of administration, at 1000 mg/kg/day, there was a slight, but statistically significant, mean body weight loss (p≤0.001). In the group given 300 mg/kg/day, mean body weight gain was also slightly lower than Controls (p≤0.05) but from Day 7 of gestation, mean body weight gain in all groups was similar to, or in excess of, Controls such that by Day 20 of gestation, all body weight values were comparable across all groups.
There was no effect on the terminal body weight adjusted for the weight of the gravid uterus. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 1000 mg/kg/day, group mean food intake was significantly lower than Controls from Day 6 to Day 9 of gestation (p≤0.001). Thereafter food intake was similar to Controls.
There was no effect on food intake following administration at 100 or 300 mg/kg/day - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- On Day 20 of gestation, there were 20, 21, 21 or 20 females pregnant with live foetuses in the groups given 0, 100, 300 or 1000 mg/kg/day, respectively. There was no effect of test item
administration on the pregnancy data. - Other effects:
- no effects observed
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: No adverse effect observed
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- not examined
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- There was no effect of the test item administration on the overall incidences of minor and variant abnormalities.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were statistically significant increases in a few minor and variant skeletal findings, largely relating to changes in the extent of ossification (p<0.05 and
p<0.01). These abnormalities were largely within the background data range and/or had no dose response. Only 3 isolated skeletal changes were outside the background range and statistically significantly higher than Controls at 300 or 1000 mg/kg/day (incomplete ossification of the cervical vertebral neural arch, interrupted costal cartilage and incomplete ossification of the sternebra). Although statistically significantly higher than Controls at 300 or 1000 mg/kg/day, these findings are isolated and disparate in nature and are considered unrelated to the test item. - Visceral malformations:
- no effects observed
- Other effects:
- no effects observed
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effect observed
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Administration of the test item to the pregnant Crl:CD(SD) rat at 100, 300 or 1000 mg/kg bw/day once daily by oral gavage from Days 6 to 19 of gestation inclusive, was generally well tolerated at all dose levels. A mild and transient effect on maternal food consumption and weight gain was observed over the first day of administration on Day 6 of gestation, with no effect on the developing conceptus or foetus. On this basis, the No-Observed-Adverse-Effect-Level (NOAEL) for maternal toxicity and the No Observed Effect Level (NOEL) for embryo-foetal development were considered to be ≥ 1000 mg/kg bw/day.
- Executive summary:
In a developmental toxicity study performed according to OECD TG No. 404 and in accordance with GLP, the test substance was administered to 22 time-mated female CD rats via oral gavage administration at dose levels of 0, 100, 300 or 1000 mg/kg bw/day at a dose volume of 10 mL/kg bodyweight from days 6 through 19 of gestation. The dose levels in this study were based on the results of an OECD 407 and an OECD 415 studies in CD rats.
Body weights, food intake and clinical observations were recorded. The animals were killed on Day 20 of gestation, a necropsy performed, and the internal organs examined for gross abnormalities. The progress and outcome of pregnancy were assessed and maternal dead body weight, gravid uterus and placenta weights were recorded. The foetuses were removed from the uterus, weighed, the sex determined and examined for external, visceral, skeletal and cartilage abnormalities.
There were no test item-related deaths or clinical observations in pregnant female rats that were related to the test item administration at any dose level.
Following the first day of administration on Day 6 of gestation, in the group given 1000 mg/kg bw/day, less food was eaten, accompanied by a slight but statistically significant mean body weight loss. In the group given 300 mg/kg bw/day, mean body weight gain was also slightly lower than Controls after the first day of administration on Day 6 of gestation. From Day 7 of
gestation, however, food intake and mean body weight gain in all groups were similar to, or in excess of Controls, such that by Day 20 of gestation, all body weight values were similar across
the groups, and mean gravid uterus weight when adjusted for body weight was comparable with Controls.
On Day 20 of gestation, there were 20, 21, 21 or 20 females pregnant with live foetuses in the groups given 0, 100, 300 or 1000 mg/kg bw/day, respectively. There was no effect of the test item on any of the pregnancy parameters.
There were no foetal abnormalities that were considered related to the test item administration.
Administration of the test item to the pregnant Crl:CD(SD) rat at 100, 300 or 1000 mg/kg bw/day once daily by oral gavage from Days 6 to 19 of gestation inclusive, was generally well tolerated at all dose levels. A mild and transient effect on maternal food consumption and weight gain was observed over the first day of administration on Day 6 of gestation, with no effect on the developing conceptus or foetus. On this basis, the No-Observed-Adverse-Effect-Level (NOAEL) for maternal toxicity and the No Observed Effect Level (NOEL) for embryo-foetal development were considered to be ≥ 1000 mg/kg bw/day.
The developmental toxicity study in the rat is classified acceptable and satisfies the guideline requirement for a developmental toxicity study (OECD 414) in rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.